Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week High – Still a Buy?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $112.01 and last traded at $110.1360, with a volume of 2880 shares. The stock had previously closed at $111.04.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ORKA. Barclays boosted their price objective on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, April 30th. Finally, Piper Sandler restated an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $134.30.

Oruka Therapeutics Price Performance

The company’s 50 day simple moving average is $87.52 and its 200 day simple moving average is $62.81. The firm has a market cap of $7.28 billion, a price-to-earnings ratio of -54.18 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other news, Director Carl Dambkowski sold 105,000 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00. Following the transaction, the director owned 73,743 shares of the company’s stock, valued at approximately $4,348,624.71. The trade was a 58.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the sale, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 181,116 shares of company stock valued at $12,045,503. Insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors have recently made changes to their positions in ORKA. Sei Investments Co. boosted its position in Oruka Therapeutics by 136.0% during the first quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after purchasing an additional 13,164 shares in the last quarter. Moody Aldrich Partners LLC purchased a new position in shares of Oruka Therapeutics in the fourth quarter valued at $3,844,000. Dimensional Fund Advisors LP acquired a new position in shares of Oruka Therapeutics during the 1st quarter worth $5,543,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Oruka Therapeutics in the 1st quarter worth about $1,811,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Oruka Therapeutics by 18.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock worth $3,559,000 after buying an additional 11,205 shares in the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.